Dipyridino phenazine compound, photoelectric device, and preparation method and application of dipyridino phenazine compound and photoelectric device
By using dipyridinophenazine compounds as electron transport layer materials in perovskite solar cells, the problems of insufficient charge extraction ability and carrier mobility of traditional organic small molecule compounds are solved, and the photoelectric conversion performance is improved.
Patent Information
- Application Number
- CN202411080945.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-26
AI Technical Summary
Traditional n-type organic small molecule compounds are inadequate charge extraction ability and carrier mobility as electron transport materials in perovskite solar cells, which affect the photoelectric conversion performance.
Dipyridophenazine compounds are used as electron transport layer materials, and through matching with the molecular energy level of the perovskite layer and enhancing electron absorption capacity, the LUMO energy level is reduced, the electron transport efficiency is improved, and nitrogen-containing heterocyclic groups and pertitanium are used. The interaction of the ore surface enhances interface interaction and improves carrier mobility.
It improves the charge extraction capability and carrier mobility, improves the photoelectric conversion performance of perovskite solar cells, and reduces the non-radiative recombination loss of carriers.
Smart Images

Figure CN119019426A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of optoelectronic devices, and in particular to a dipyridophenazine compound, an optoelectronic device, and a preparation method and application thereof. Background Art
[0002] Perovskite solar cells (PSCs) have received widespread attention in recent years as an efficient and low-cost alternative to traditional solar energy conversion. The electron transport layer in inverse perovskite solar cells plays an important role in extracting and transporting carriers, blocking holes, regulating the interface energy level structure and inhibiting charge recombination. However, the currently commonly used fullerenes and their derivatives as electron transport materials have problems such as high cost, single energy level adjustability, and poor stability in air. Researchers have found that compared with fullerenes and their derivatives, n-type organic small molecule compounds have high thermal stability and chemical stability, low synthesis cost, good batch reproducibility, and multifunctional reaction sites that make them easy to modify. Therefore, they are expected to replace fullerenes as electron transport materials.
[0003] However, traditional n-type organic small molecule compounds used as electron transport materials still have problems with insufficient charge extraction ability and carrier mobility, which affects the photoelectric conversion performance of the device. Summary of the invention
[0004] Based on this, some embodiments of the present application provide a dipyridophenazine compound, which is used in an electron transport layer to help improve the charge extraction capability and carrier mobility, thereby improving the photoelectric conversion performance of the device.
[0005] In addition, other embodiments of the present application also provide a preparation method, application, optoelectronic device and preparation method thereof of a dipyridophenazine compound.
[0006] A dipyridophenazine compound having the following general structural formula:
[0007]
[0008] Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -Cn SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0009] In some embodiments, each L is independently substituted or unsubstituted C5-C 10 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C5~C 10 A nitrogen-containing heteroaryl group;
[0010] Optionally, each L is independently one of a substituted or unsubstituted pyridyl, pyrazolyl, pyrrolyl, pyrazolopyridyl, pyrrolopyridyl, quinolyl and isoquinolyl.
[0011] In some embodiments, the dipyridophenazine compound has the following general structural formula:
[0012]
[0013] In the formula, R represents the substituent, and m is an integer of 0-4.
[0014] In some embodiments, each of the substituents is independently selected from one of halogen, amide, ester, carboxyl and carbonyl;
[0015] Optionally, each of the substituents is independently selected from one of halogen, C1-C6 amide and C1-C6 ester.
[0016] In some embodiments, one or more of the following structural formulas are selected:
[0017]
[0018] A method for preparing a dipyridophenazine compound comprises the following steps:
[0019] Reacting compound c with 1,10-phenanthroline-5,6-dione to generate a dipyridophenazine compound;
[0020] Wherein, the structural formula of the compound c is The structural formula of the dipyridophenazine compound is
[0021]
[0022] In the formula, each L is independently substituted or unsubstituted C4 to C 20A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 heteroaryl, -CnOR1 and -CnSR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0023] In some embodiments, the compound c is prepared by the following steps:
[0024] reacting compound a with 4,7-dibromo-5,6-dinitrobenzothiadiazole to generate compound b;
[0025] Reducing the nitro group in the compound b to generate the compound c;
[0026] Wherein, the structural formula of the compound a is Or -B(OH)2, the structural formula of compound b is
[0027]
[0028] Application of the above-mentioned dipyridophenazine compound or the dipyridophenazine compound prepared by the above-mentioned preparation method in the preparation of semiconductor devices.
[0029] A photoelectric device comprises a first electrode, a second electrode and a functional layer arranged between the first electrode and the second electrode, wherein the material of the functional layer comprises a dipyridophenazine compound, and the dipyridophenazine compound has the following general structural formula:
[0030]
[0031] Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0032] In some embodiments, the functional layer includes an electron transport layer, and the optoelectronic device further includes a photoelectric conversion layer and a hole transport layer disposed between the first electrode and the second electrode, and the photoelectric conversion layer is disposed between the electron transport layer and the hole transport layer.
[0033] A method for preparing a photoelectric device comprises the following steps:
[0034] Forming a first electrode, a second electrode and a functional layer in a stacked arrangement, wherein the functional layer is stacked between the first electrode and the second electrode, to prepare a photoelectric device;
[0035] Wherein, the material of the functional layer includes a dipyridophenazine compound, and the dipyridophenazine compound has the following general structural formula:
[0036]
[0037] Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0038] In some embodiments, the functional layer is prepared by a solution method, and the functional material is dissolved in 1,2-dichlorobenzene to make the concentration of the functional material be 1 mg / mL to 20 mg / mL, and the functional material includes the dipyridophenazine compound;
[0039] Optionally, the functional layer comprises an electron transport layer.
[0040] The above-mentioned dipyridophenazine compounds use dipyridophenazine thiadiazole (DTP) as the parent unit, and are modified with nitrogen-containing heterocyclic groups or nitrogen-containing heteroaryl groups, so that they have a molecular energy level that is more compatible with the perovskite layer, and can enhance the n-type characteristics of the material due to its electron-withdrawing ability, reduce the LUMO energy level, and thus can better extract and transport electrons, effectively reduce the non-radiative recombination loss of carriers, and improve the performance of the device. In addition, the N atoms with lone electron pairs in the nitrogen-containing heterocyclic groups or nitrogen-containing heteroaryl groups can interact with uncoordinated B-site ions such as Pb ions on the surface of the perovskite layer, effectively enhance the interfacial interaction between the electron transport layer and the perovskite, and passivate positively charged defects, improve carrier mobility, and enhance the performance of the device. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0042] Figure 1 This is a schematic diagram of the structure of an optoelectronic device in some embodiments of the present application. DETAILED DESCRIPTION
[0043] In order to facilitate the understanding of the present application, the present application will be described more comprehensively below in conjunction with the specific embodiments. The preferred embodiments of the present application are provided in the specific embodiments. However, the present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present application more thorough and comprehensive.
[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the present application belongs. The terms used herein in the specification of the present application are only for the purpose of describing specific embodiments and are not intended to limit the present application. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0045] Unless otherwise specified or there is a contradiction, the terms and phrases used in this application have the following meanings:
[0046] In this application, "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features.
[0047] In the description of the present application, “plurality” means at least two, for example, two, three, etc., unless otherwise clearly and specifically defined.
[0048] In this application, "one or several" refers to any one, any two or more of the listed items. Among them, "several" refers to any two or more of the listed items.
[0049] In this application, the percentage concentration involved, unless otherwise specified, refers to the final concentration. The final concentration refers to the proportion of the added component in the system after the addition of the component.
[0050] In this document, "further", "further", "particularly", "for example", "such as", "example", "for example", etc. are used for descriptive purposes, indicating that the previous and subsequent technical solutions are related in terms of the content covered, but should not be understood as a limitation on the previous technical solution, nor can it be understood as a limitation on the protection scope of this document. In this document, unless otherwise specified, A (such as B) means that B is a non-limiting example of A, and it can be understood that A is not limited to B.
[0051] Herein, "optionally", "optional", and "optional" mean optional, that is, any one of the two parallel schemes of "yes" or "no". If multiple "optional" items appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" item is independent of each other. In this application, descriptions such as "optionally contain", "optionally include", etc. mean "contain or not contain". "Optional component X" means that component X exists or does not exist, or means that component X is contained or not contained.
[0052] When a numerical range is disclosed in this application, the above range is considered to be continuous and includes the minimum and maximum values of the range, as well as every value between such minimum and maximum values. Further, when a range refers to an integer, every integer between the minimum and maximum values of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be combined. In other words, unless otherwise indicated, all ranges disclosed in this application should be understood to include any and all subranges included therein.
[0053] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0054] The terms "including" and "having" and any variations thereof in the embodiments of the present application are intended to cover non-exclusive inclusions. For example, a process, method, system, product, or device that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units that are not listed, or may optionally include other steps or components that are inherent to these processes, methods, products, or devices.
[0055] Reference to "embodiments" in this application means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described in this application may be combined with other embodiments.
[0056] The term "alkyl" refers to a saturated hydrocarbon containing primary (normal) carbon atoms, secondary carbon atoms, tertiary carbon atoms, quaternary carbon atoms, or a combination thereof. Phrases containing this term, for example, "C1-C 10 "Alkyl" refers to an alkyl group containing 1 to 9 carbon atoms, and each occurrence can be independently C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, C9 alkyl or C 10Alkyl. Suitable examples include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(C H3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (- CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH( 2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3 and octyl (-(CH2)7CH3).
[0057] The term "cycloalkyl" refers to a non-aromatic hydrocarbon containing ring carbon atoms, which may be a monocyclic alkyl, a spirocyclic alkyl, or a bridged cycloalkyl. Phrases containing this term, for example, "C3-C 10 "Cycloalkyl" refers to a cycloalkyl group containing 3 to 10 carbon atoms, each occurrence of which can be independently C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, C7 cycloalkyl, C8 cycloalkyl, C9 cycloalkyl or C 10 Cycloalkyl. Suitable examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. In addition, "cycloalkyl" may also contain one or more double bonds, and representative examples of cycloalkyl containing double bonds include cyclopentenyl, cyclohexenyl, cyclohexadienyl, and cyclobutadienyl.
[0058] "Cycloalkylalkyl" refers to a hydrocarbon group derived from an alkyl group in which at least one hydrogen atom bonded to a carbon atom is replaced by a cycloalkyl group. Phrases containing this term, such as C4-C 10 Cycloalkylalkyl is an alkyl group substituted by a cyclic alkyl group having 4 to 10 carbon atoms, for example cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, cyclooctylethyl, cyclopropylpropyl, cyclobutylpropyl, cyclopentylpropyl, cyclohexylpropyl, cycloheptylpropyl or cyclooctylpropyl, preferably cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclopropylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, cyclopropylpropyl, cyclopentylpropyl, cyclohexylpropyl or cycloheptylpropyl.
[0059] "Aryl" refers to an aromatic hydrocarbon group derived from an aromatic ring compound by removing a hydrogen atom. It can be a monocyclic aromatic group, a condensed aromatic group, or a polycyclic aromatic group. For polycyclic rings, at least one is an aromatic ring system. For example, "C5-C 20 "Aryl" refers to an aromatic group containing 5 to 20 carbon atoms, and each occurrence can be independently C5 aromatic group, C6 aromatic group, C 10 Aryl, C 14 Aryl, C 18 Aryl or C 20 Suitable examples include, but are not limited to, benzene, biphenyl, naphthalene, anthracene, phenanthrene, perylene, triphenylene, and derivatives thereof.
[0060] "Heteroaryl" means that at least one carbon atom in an aryl group is replaced by a non-carbon atom, such as a nitrogen atom, an oxygen atom, or a sulfur atom. 10 The term "heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms, which, at each occurrence, may be independently C3 heteroaryl, C4 heteroaryl, C5 heteroaryl, C6 heteroaryl, C7 heteroaryl or C8 heteroaryl. Suitable examples include, but are not limited to, furan, benzofuran, thiophene, benzothiophene, pyrrole, pyrazole, triazole, imidazole, oxazole, oxadiazole, thiazole, tetrazole, indole, carbazole, pyrroloimidazole, pyrrolopyrrole, thienopyrrole, thienothiophene, furopyrrole, furanofuran, thienofuran, benzisoxazole, benzisothiazole, benzimidazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, quinoline, isoquinoline, o-naphthyridine, quinoxaline, phenanthridine, primary idine, quinazoline and quinazolinone.
[0061] "Heteroalkyl" means that at least one carbon atom is replaced by a non-carbon atom on the basis of an alkyl group, and the non-carbon atom can be an N atom, an O atom, an S atom, etc. For example, if the carbon atom connected to the parent core structure in the alkyl group is replaced by a non-carbon atom, the resulting heteroalkyl group is an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CH3)2, etc.) or a thioalkyl group (e.g., -SCH3). If the carbon atom not connected to the parent core structure in the alkyl group is replaced by a non-carbon atom, the resulting heteroalkyl group is an alkyl ether (e.g., -CH2CH2-O-CH3, etc.), an alkylamine (e.g., -CH2NHCH3, -CH2N(CH3)2, etc.) or a thioalkyl ether (e.g., -CH2-S-CH3). If the terminal carbon atom of the alkyl group is replaced by a non-carbon atom, the resulting heteroalkyl group is a hydroxyalkyl group (e.g., -CH2CH2-OH), an aminoalkyl group (e.g., -CH2NH2) or an alkylthiol group (e.g., -CH2CH2-SH). Phrases containing this term, for example, "C1-C9 heteroalkyl" refers to heteroalkyl groups containing 1 to 9 carbon atoms, and each occurrence can be independently C2 heteroalkyl, C3 heteroalkyl, C4 heteroalkyl, C5 heteroalkyl, C7 heteroalkyl, C8 heteroalkyl or C9 heteroalkyl.
[0062] "Heterocyclyl" means that at least one carbon atom on the basis of a cycloalkyl group is replaced by a non-carbon atom, and the non-carbon atom can be an N atom, an O atom, an S atom, etc., and can be a saturated ring or a partially unsaturated ring. Phrases containing this term, for example, "C4-C9 heterocyclyl" means a heterocyclyl group containing 4 to 9 carbon atoms, each occurrence of which can be independently C4 heteroalkyl, C6 heteroalkyl, C7 heteroalkyl, C8 heteroalkyl or C9 heteroalkyl. Suitable examples include, but are not limited to: dihydropyridyl, tetrahydropyridyl (piperidyl), tetrahydrothienyl, sulfur-oxidized tetrahydrothienyl, tetrahydrofuranyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydroindole.
[0063] The amide group refers to an organic group including -CON-. The C1-C6 amide group refers to a straight or branched amide group having 1 to 6 carbon atoms, such as formamide, acetamide, propionamide, isopropionamide, butyramide, isobutyramide, tert-butyramide, sec-butyramide, valeramide, pivaleramide, hexanamide, etc.
[0064] An ester group refers to an organic group including a -COO- bond. A C1-C6 ester group refers to a straight or branched ester group having 1 to 6 carbon atoms. For example: methyl ester group, ethyl ester group, isopropyl ester group, butyl ester group, isobutyl ester group, tert-butyl ester group, sec-butyl ester group, pentyl ester group, neopentyl ester group, hexyl ester group, etc.
[0065] Carboxyl refers to an organic group including -COOH. C1-C6 carboxyl refers to a straight or branched carboxyl group having 1 to 6 carbon atoms. For example: formic acid, acetic acid, isopropionic acid, butyric acid, isobutyric acid, tert-butyric acid, sec-butyric acid, valeric acid, neopentanoic acid, hexanoic acid, etc.
[0066] The names of some abbreviations involved in this article are as follows:
[0067] HTM: hole transport material; HTL: hole transport layer; ETM: electron transport material; ETL: electron transport layer; ITO: conductive glass; PVK: perovskite; PSC: perovskite solar cell; BCP: 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline.
[0068] The first aspect of the present application provides a dipyridophenazine compound having the following general structural formula:
[0069]
[0070] Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group is substituted, and the substituent is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C3~C 10 Cycloalkyl, C5~C 10 Aryl, C3~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein R1 is selected from hydrogen, C1~C 10 Alkyl, C3~C 20 Cycloalkyl, C4~C 10 The carbon in any of the groups may be selectively substituted by N, O or S; and n represents an integer between 0 and 10.
[0071] The above-mentioned dipyridophenazine compounds use dipyridylthiadiazolephenazine (DTP) as the parent unit, and are modified with nitrogen-containing heterocyclic groups or nitrogen-containing heteroaryl groups to have a molecular energy level that is more compatible with the perovskite layer, and can enhance the n-type characteristics of the material due to its electron-withdrawing ability, reduce the LUMO energy level, and thus can better extract and transport electrons, effectively reduce the non-radiative recombination loss of carriers, and improve the performance of the device. In addition, the N atoms with lone electron pairs in the nitrogen-containing heterocyclic group or nitrogen-containing heteroaryl group can interact with the uncoordinated Pb ions on the surface of the perovskite layer, effectively enhance the interfacial interaction between the electron transport layer and the perovskite, and passivate positively charged defects, improve the carrier mobility, and enhance the performance of the device.
[0072] In addition, in the above-mentioned dipyridophenazine compounds, if L is hydrogen, that is, if it does not contain a substituent, the HOMO energy level of the molecule is close to that of MAPbI3, resulting in insufficient hole blocking ability and ultimately poor device performance. However, by selecting the L group, it has a molecular energy level that is more compatible with the perovskite layer, and can enhance the n-type characteristics of the material due to its electron-withdrawing ability, reduce the LUMO energy level, and thus can better extract and transmit electrons, effectively reduce the non-radiative recombination loss of carriers, and improve the performance of the device.
[0073] In some embodiments, each L is independently substituted or unsubstituted C4 to C 10 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 10 Further, each L is independently a substituted or unsubstituted C6 to C 10 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C6~C 10 Further, each L is independently a substituted or unsubstituted pyridyl, pyrazolyl, pyrrolyl, pyrazolopyridyl, pyrrolopyridyl, quinolyl (also known as benzopyridyl) and isoquinolyl.
[0074] In some embodiments, each L contains a pyridyl group. For example, each L is independently a substituted or unsubstituted pyridyl group, or each L is independently a substituted or unsubstituted pyrazolopyridyl group, a pyrrolopyridyl group, a quinolyl group, and an isoquinolyl group.
[0075] In some embodiments, the dipyridophenazine compound has the following general structural formula:
[0076]
[0077] In the formula, R represents the substituent, and m is an integer of 0-4.
[0078] It can be understood that in the above general structural formula, R can be connected to any position of the nitrogen-containing heterocyclic group or the nitrogen-containing heteroaryl group, m represents the number of R groups, and the number of R can be 0, 1, 2, 3 or 4. In some embodiments, m is 0, 1 or 2.
[0079] In some embodiments, each of the substituents is independently selected from one of halogen, amide, ester, carboxyl and carbonyl. Further, each of the substituents is independently selected from one of halogen, C1-C6 amide and C1-C6 ester. Further, each of the substituents is independently selected from one of fluorine, C1-C6 amide and C1-C6 ester.
[0080] In some embodiments, each of the substituents is independently selected from one of an amide group, an ester group, a carboxyl group, and a carbonyl group. Further, each of the substituents is independently selected from one of a C1-C6 amide group, a C1-C6 ester group, a C1-C6 carboxyl group, and a C1-C6 carbonyl group. Further, each of the substituents is independently selected from one of a C1-C6 amide group and a C1-C6 ester group. Experiments have shown that the presence of a carbon-oxygen double bond or a carbon-nitrogen bond in the substituent is beneficial to further improve device performance.
[0081] In some embodiments, the dipyridophenazine compound is selected from one or more of the following structural formulas:
[0082]
[0083] In some embodiments, the dipyridophenazine compound is selected from one or more of the following structural formulas:
[0084]
[0085] The second aspect of the present application provides a method for preparing a dipyridophenazine compound, comprising the following steps:
[0086] Reacting compound c with 1,10-phenanthroline-5,6-dione to generate a dipyridophenazine compound;
[0087] Wherein, the structural formula of the compound c is The structural formula of the dipyridophenazine compound is
[0088]
[0089] In the formula, each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 heteroaryl, -CnOR1 and -CnSR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0090] Among them, the structural formula of 1,10-phenanthroline-5,6-dione is
[0091] In some embodiments, the temperature of the reaction of compound c and 1,10-phenanthroline-5,6-dione is 80° C. to 180° C., and the time is 1 h to 48 h. Specifically, compound c and 1,10-phenanthroline-5,6-dione are reacted in an acetic acid solution at 80° C. to 180° C. for 1 h to 48 h.
[0092] In a specific example, the temperature for reacting compound c with 1,10-phenanthroline-5,6-dione can be, but is not limited to, 80°C, 100°C, 110°C, 120°C, 130°C, 140°C, 150°C, 160°C, 170°C, 180°C, or a range consisting of any two of these values. Optionally, the reaction temperature is 90°C to 110°C.
[0093] In a specific example, the reaction time of compound c and 1,10-phenanthroline-5,6-dione can be, but is not limited to, 1 h, 2 h, 6 h, 9 h, 12 h, 15 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, or a range consisting of any two of these values. Optionally, the reaction time is 8 h to 24 h.
[0094] In some embodiments, the compound c is prepared by the following steps:
[0095] reacting compound a with 4,7-dibromo-5,6-dinitrobenzothiadiazole to generate compound b;
[0096] Reducing the nitro group in the compound b to generate the compound c;
[0097] Wherein, the structural formula of the compound a is Or -B(OH)2, the structural formula of compound b is The structural formula of 4,7-dibromo-5,6-dinitrobenzothiadiazole is
[0098] In some embodiments, the preparation steps of the dipyridophenazine compound are as follows:
[0099] Step S110: reacting compound a with 4,7-dibromo-5,6-dinitrobenzothiadiazole to generate compound b.
[0100] Specifically, in step S110, an alkaline agent and a catalyst are also added. The alkaline agent can be, but is not limited to, potassium carbonate, and the catalyst is a palladium catalyst. Specifically, the catalyst is tetrakis(triphenyl)phosphine palladium (Pd(PPh3)4).
[0101] In some of the embodiments, the molar ratio of compound a to 4,7-dibromo-5,6-dinitrobenzothiadiazole is (3-3.5):1. The molar ratio of 4,7-dibromo-5,6-dinitrobenzothiadiazole to the alkaline agent and the catalyst is 1:(2.5-3.5):(0.1-0.3).
[0102] In some embodiments, the temperature for reacting compound a with 4,7-dibromo-5,6-dinitrobenzothiadiazole is 50° C. to 180° C., and the time is 1 h to 48 h.
[0103] In a specific example, the temperature for reacting compound a with 4,7-dibromo-5,6-dinitrobenzothiadiazole can be, but is not limited to, 50°C, 60°C, 80°C, 100°C, 110°C, 120°C, 130°C, 140°C, 150°C, 160°C, 170°C, 180°C, or a range consisting of any two of these values. Optionally, the reaction temperature is 80°C to 100°C.
[0104] In a specific example, the reaction time of compound a and 4,7-dibromo-5,6-dinitrobenzothiadiazole is 1 h to 48 h. For example, the reaction time can be, but is not limited to, 1 h, 2 h, 6 h, 9 h, 12 h, 15 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, or a range consisting of any two of these values. Optionally, the reaction time is 12 h to 24 h.
[0105] In some embodiments, step S110 includes: mixing compound a, 4,7-dibromo-5,6-dinitrobenzothiadiazole, potassium carbonate (K2CO3), and tetrakis(triphenyl)phosphine palladium (Pd(PPh3)4), reacting at 50-180°C for 1-48 hours under nitrogen protection. After the reaction, cooling the mixture and diluting it with water, extracting it with ethyl acetate (EA), and purifying it to obtain compound b.
[0106] Step S120: reducing the nitro group in the compound b to generate the compound c.
[0107] In some of the embodiments, zinc powder and ammonium chloride are used to reduce the nitro group in compound b. Specifically, compound b is mixed with zinc powder and zinc chloride in a mixed solvent of dichloromethane, methanol and water, reacted at 20-80° C. for 1-48 h, filtered, the filter cake is washed with DCM, and the filtrate is concentrated in vacuo to obtain compound c.
[0108] In some embodiments, the reaction temperature is 20° C. to 40° C., and the reaction time is 2 h to 6 h.
[0109] It can be understood that the above only provides a method for reducing the nitro group in compound b, but is not limited thereto, and other methods commonly used in the art may also be used.
[0110] Step S130: reacting compound c with 1,10-phenanthroline-5,6-dione to generate a dipyridophenazine compound.
[0111] Specifically, the synthesis route of the dipyridophenazine compounds is as follows:
[0112]
[0113] The DTP unit was modified and a PDTP derivative with a substituent was successfully synthesized. The synthesis is simple and the modification is convenient. The modified PDTP unit has a higher solubility and can be adapted to the traditional spin coating process.
[0114] The third aspect of the present application provides a use of the above-mentioned dipyridophenazine compound in the preparation of semiconductor devices.
[0115] The semiconductor device may be, but is not limited to, a solar cell and an organic light emitting diode.
[0116] A fourth aspect of the present application provides an optoelectronic device, comprising a first electrode, a second electrode, and a functional layer disposed between the first electrode and the second electrode, wherein the material of the functional layer comprises a dipyridophenazine compound, and the dipyridophenazine compound has the following general structural formula:
[0117]
[0118] Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0119] The specific dipyridophenazine compounds are as described above and will not be described in detail here.
[0120] In some embodiments, the optoelectronic device may be, but is not limited to, a solar cell and an organic light emitting diode.
[0121] In some embodiments, the functional layer includes an electron transport layer. It is understood that the functional layer is not limited to the electron transport layer, but can also be other layers, such as a photoelectric conversion layer such as a light-emitting layer.
[0122] In some embodiments, the functional layer includes an electron transport layer, and the optoelectronic device further includes a photoelectric conversion layer and a hole transport layer disposed between the first electrode and the second electrode, and the photoelectric conversion layer is disposed between the electron transport layer and the hole transport layer.
[0123] In some embodiments, the material of the hole transport layer includes an inorganic hole transport material and an organic hole transport material, wherein the inorganic hole transport material includes one or more of nickel oxide (NiOx) and tin dioxide (SnO2). The organic hole transport material includes one or more of a polymer and a self-assembled monomolecular material. Specifically, the polymer includes one or more of poly(bis(4-phenyl)(2,4,6-trimethylphenyl)amine) (PTAA) and poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS). The self-assembled monomolecular material includes one or more of [4-(3,6-dimethyl-9H-carbazole-9-yl)butyl]phosphoric acid (Me-4PACz) and 2-[(2-chlorophenyl)(phenyl)amino]ethyl benzoate (2PACz).
[0124] In some of the embodiments, the hole transport layer is a single-layer structure, for example, the hole transport layer is an inorganic hole transport layer, or the hole transport layer is a single-layer structure of a blend of an inorganic hole transport material and an organic hole transport material.
[0125] In other embodiments, the hole transport layer is a stacked double-layer structure, for example, a two-layer structure including an inorganic hole transport sublayer and an organic hole transport sublayer. In a specific example, the hole transport layer includes an inorganic hole transport sublayer and a self-assembled monolayer.
[0126] In some embodiments, the photoelectric conversion layer is a light absorbing layer or a light emitting layer. For example, the photoelectric conversion layer is a perovskite light absorbing layer. Specifically, the photoelectric device is a solar cell, and the photoelectric conversion layer is a light absorbing layer, for example, the photoelectric conversion layer is a perovskite light absorbing layer. It is understood that in some other embodiments, the photoelectric device can also be an organic light emitting diode, and the photoelectric conversion layer is a light emitting layer.
[0127] In some embodiments, the optoelectronic device is a trans-structure. Figure 1 The photoelectric device 100 includes a first electrode 120 , a hole transport layer 130 , a photoelectric conversion layer 140 , an electron transport layer 150 , a hole blocking layer 160 , and a second electrode 170 which are sequentially stacked on a substrate 110 .
[0128] In some embodiments, the substrate 110 includes, but is not limited to, glass.
[0129] In some embodiments, the material of the first electrode 120 includes a transparent conductive oxide. Specifically, the material of the first electrode includes one of aluminum-doped zinc oxide (AZO), zinc oxide (ZnO), titanium oxide (TiO2), niobium-doped titanium dioxide (NTO), indium tin oxide (ITO), fluorine-doped tin oxide (FTO), indium tungsten oxide (IWO) and indium gallium zinc oxide (InGaZnO).
[0130] In some embodiments, the material of the hole transport layer 130 includes an inorganic hole transport material and an organic hole transport material, wherein the inorganic hole transport material includes one or more of nickel oxide (NiOx) and tin dioxide (SnO2). The organic hole transport material includes one or more of a polymer and a self-assembled monomolecular material. Specifically, the polymer includes one or more of poly(bis(4-phenyl)(2,4,6-trimethylphenyl)amine) (PTAA) and poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS). The self-assembled monomolecular material includes one or more of [4-(3,6-dimethyl-9H-carbazole-9-yl)butyl]phosphoric acid (Me-4PACz) and 2-[(2-chlorophenyl)(phenyl)amino]ethyl benzoate (2PACz).
[0131] In some embodiments, the photoelectric conversion layer 140 is a perovskite light absorbing layer. Specifically, the material of the photoelectric conversion layer 140 includes ABX3, wherein the A-position cation (A + ) including formamidinium ion (FA+ ), cesium ion (Cs + ) and methylamine ion (MA + ) or more. 2+ Including lead ions (Pb 2+ ) and tin (Sn 2+ ) or more. - Including halogen ions, specifically, X - Including bromide ion (Br - ) and iodide ion (I - ) one or more of the following.
[0132] In some embodiments, the material of the electron transport layer 150 includes the above-mentioned dipyridophenazine compound.
[0133] In some embodiments, the material of the hole blocking layer 160 includes one or more of 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline (BCP) and zirconium acetylacetonate.
[0134] In some embodiments, the material of the second electrode 170 includes one or more of silver, copper, TCO and carbon.
[0135] It can be understood that in some other embodiments, the hole blocking layer 160 may also be omitted.
[0136] A fifth aspect of the present application provides a method for preparing a photoelectric device, comprising the following steps:
[0137] Forming a first electrode, a second electrode and a functional layer in a stacked arrangement, wherein the functional layer is stacked between the first electrode and the second electrode, to prepare a photoelectric device;
[0138] Wherein, the material of the functional layer includes a dipyridophenazine compound, and the dipyridophenazine compound has the following general structural formula:
[0139]
[0140] Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -Cn OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
[0141] In some embodiments, the functional layer is formed by a solution method. Specifically, the functional material is dissolved in a solvent to make the concentration of the functional material be 1 mg / mL to 20 mg / mL, and the functional material includes the dipyridophenazine compound.
[0142] In some embodiments, the solvent includes 1,2-dichlorobenzene.
[0143] In a specific example, the concentration of the functional material can be, but is not limited to, 1 mg / mL, 2 mg / mL, 5 mg / mL, 8 mg / mL, 10 mg / mL, 12 mg / mL, 15 mg / mL, 18 mg / mL, 20 mg / mL or a range consisting of any two of these values.
[0144] In some embodiments, the functional layer includes an electron transport layer.
[0145] In some embodiments, the optoelectronic device includes a first electrode, a hole transport layer, a photoelectric conversion layer, an electron transport layer, a hole blocking layer, and a second electrode stacked in sequence on a substrate. The method for preparing the optoelectronic device includes the following steps:
[0146] Step S210: forming a hole transport layer on the surface of the first electrode.
[0147] Specifically, a solution containing a hole transport material is prepared, and the solution containing the hole transport material is applied on the substrate layer to prepare the hole transport layer. The specific application method may be, but is not limited to, coating.
[0148] Step S220: forming a photoelectric conversion layer on the surface of the hole transport layer.
[0149] In some embodiments, the photoelectric conversion layer is a perovskite light absorbing layer. Specifically, step S220 includes: preparing a perovskite precursor solution, applying the perovskite precursor solution on the hole transport layer, and preparing the photoelectric conversion layer.
[0150] Step S230: forming an electron transport layer on the surface of the photoelectric conversion layer.
[0151] The steps of forming the electron transport layer are as described above.
[0152] Step S240: forming a hole blocking layer on the electron transport layer.
[0153] Specifically, a solution containing a hole blocking material is prepared, and the solution containing the hole blocking material is applied on the surface of the electron transport layer to prepare the hole blocking layer.
[0154] Step S250: forming a second electrode on the surface of the hole blocking layer to prepare a photoelectric device.
[0155] In some embodiments, the second electrode is formed by evaporation.
[0156] It can be understood that in some embodiments, step S240 may be omitted, that is, no hole blocking layer is included.
[0157] It can be understood that the above only provides a relatively specific method for preparing a photoelectric device, but is not limited thereto, and the preparation method can also be adjusted according to different structures of the photoelectric device.
[0158] In order to make the purpose and advantages of the present application clearer, the dipyridophenazine compounds of the present application and their effects are further described in detail in conjunction with specific examples. It should be understood that the specific examples described here are only used to explain the present application and shall not be used to limit the present application. The following examples do not include other components except for unavoidable impurities unless otherwise specified. The drugs and instruments used in the examples are conventionally selected in the art unless otherwise specified. The experimental methods for which specific conditions are not specified in the examples are implemented according to conventional conditions, such as the conditions described in the literature and books or the methods recommended by the manufacturer.
[0159] 1. Synthesis Example
[0160] Synthesis Example 1
[0161] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0162]
[0163] , the preparation steps are as follows:
[0164] (1) Under nitrogen protection, 1H-pyrrolo[3,2-B]pyridine-6-boronic acid pinacol ester (3.0 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (3.2 mmol), and Pd(PPh3)4 (0.1 mmol) were added to a reaction vessel, the temperature was raised to 80°C, and the mixture was stirred for reaction for 12 hours. After the reaction was completed, the mixture was cooled and diluted with water, extracted with ethyl acetate (EA), and purified to obtain intermediate 1 (yield 78%, 0.78 mmol).
[0165] (2) The intermediate product 1 (0.78 mmol) obtained in the previous step was added to a mixed solvent of dichloromethane (DCM), methanol (MeOH) and water in a volume ratio of 1:1:1, and then ammonium chloride (28 mmol) and zinc powder (92 mmol) were added. The mixture was reacted at 25°C for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was collected and concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.78 mmol) were dissolved in acetic acid, refluxed in an oil bath at 110°C for 24 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 1, i.e., the dipyridophenazine compound of this synthetic example (yield 46%, 0.36 mmol, 207 mg).
[0166] The characterization data of compound 1 are as follows:
[0167] 1 H NMR (500MHz, CDCl3): δ9.23 (d, J=1.6Hz, 2H), 8.98 (dd, J=4.3, 2.0Hz, 2H), 8.83 (dd, J=8.6, 2.0Hz, 2H), 7.85 (d, J = 1.8 Hz, 2H), 7.66 (dd, J = 8.5, 4.1 Hz, 2H), 7.53 (dd, J = 8.0, 3.6 Hz, 2H), 6.96 (d, J = 3.7 Hz, 2H).
[0168] 13 C NMR (125MHz, CDCl3): δ156.14,151.30,146.89,146.75,144.68,143.84,141. 75,134.80,127.68,127.25,126.30,124.92,123.57,122.98,116.46,104.32.
[0169] FDMS(m / z):[M + ]calcd.for C 32 H 16 N10 S,573.13;found,573.14.
[0170] Synthesis Example 2
[0171] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0172]
[0173] , the preparation steps are as follows:
[0174] (1) Under nitrogen protection, 2-fluoro-5-pyridineboronic acid (3.0 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (3.2 mmol), and Pd(PPh3)4 (0.1 mmol) were added to a reaction vessel, and the temperature was raised to 80°C and stirred for reaction for 12 hours. After the reaction, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 2 (yield 69%, 0.69 mmol).
[0175] (2) The intermediate product 2 (0.69 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (26 mmol) and zinc powder (89 mmol) were added. The mixture was reacted at 25°C for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was collected and concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.69 mmol) were dissolved in acetic acid, refluxed in an oil bath at 100°C for 12 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 2, i.e., the dipyridophenazine compound of this synthetic example (yield 38%, 0.26 mmol, 139 mg).
[0176] The characterization data of compound 2 are as follows:
[0177] 1 H NMR (500MHz, CDCl3): δ9.04 (d, J=2.2Hz, 2H), 8.98 (dd, J=4.3, 2.0Hz, 2H), 8.83 (dd, J=8.6, 2.0 Hz, 2H), 8.61 (ddd, J=8.1, 5.0, 2.3Hz, 2H), 7.66 (dd, J=8.5, 4.1Hz, 2H), 7.06 (t, J=8.0Hz, 2H).
[0178] 13C NMR (125MHz, CDCl3): δ163.69,161.67,156.84,151.97,151.86,151.30,147.31,146.75,1 41.75,139.67,139.60,134.80,129.07,129.04,124.92,124.04,123.57,111.59,111.43.
[0179] FDMS(m / z):[M + ]calcd.for C 28 H 12 F2N8S,531.09; found,531.08.
[0180] Synthesis Example 3
[0181] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0182]
[0183] , the preparation steps are as follows:
[0184] (1) Under nitrogen protection, 7-azaindole-5-boronic acid pinacol ester (3.0 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (3.0 mmol), and Pd(PPh3)4 (0.3 mmol) were added to a reaction vessel, and the temperature was raised to 90°C and stirred for reaction for 16 hours. After the reaction was completed, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 3 (yield 54%, 0.54 mmol).
[0185] (2) The intermediate product 3 (0.54 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25°C for 2 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.54 mmol) were dissolved in acetic acid, refluxed in an oil bath at 100°C for 12 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 3, i.e., the dipyridophenazine compound of this synthetic example (yield 40%, 0.22 mmol, 124 mg).
[0186] The characterization data of compound 3 are as follows:
[0187] 1H NMR (500MHz, CDCl3): δ9.08 (d, J=1.6Hz, 2H), 8.98 (dd, J=4.3, 2.0Hz, 2H), 8.94 (t, J=1.7 Hz, 2H), 8.83 (dd, J = 8.6, 2.0 Hz, 2H), 8.37 ( d, J = 1.6 Hz, 2H), 7.66 ( dd, J = 8.5, 4.1 Hz, 2H).
[0188] 13 C NMR (125MHz, CDCl3): δ156.68,153.16,151.30,150.83,147.25,146.75,1 41.75,134.80,133.55,129.39,124.92,124.61,123.57,123.39,118.49.
[0189] FDMS(m / z):[M + ]calcd.for C 30 H 14 N 12 S,575.12; found,575.11,
[0190] Synthesis Example 4
[0191] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0192] , the preparation steps are as follows:
[0193] (1) Under nitrogen protection, B-[2-[(2,2-dimethyl-1-oxopropyl)amino]-3-pyridine]boric acid (3.3 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (2.5 mmol), and Pd(PPh3)4 (0.3 mmol) were added to a reaction vessel, and the temperature was raised to 80°C and stirred for reaction for 12 hours. After the reaction was completed, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 4 (yield 62%, 0.62 mmol).
[0194] (2) The intermediate product 4 (0.62 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25°C for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.62 mmol) were dissolved in acetic acid, refluxed in an oil bath at 100°C for 12 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 4, i.e., the dipyridophenazine compound of this synthetic example (yield 60%, 0.37 mmol, 258 mg).
[0195] The characterization data of compound 4 are as follows:
[0196] 1 H NMR (500MHz, CDCl3): δ9.06–8.89(m,4H),8.83(dd,J=8.6,2.0Hz,2H),8.43(dd,J=4.4,2.2Hz,2H), 8.21(dd,J=7.9,2.2Hz,2H), 7.66(dd,J=8.5,4.1Hz,2H), 7.37(dd,J=7.9,4.4Hz,2H), 1.14(s,18H).
[0197] 13 C NMR (125MHz, CDCl3): δ177.10,155.01,151.78,151.30,148.43,146.75,144.60, 141.79,140.00,134.80,124.92,124.21,123.57,121.55,120.30,39.53,27.57.
[0198] FDMS(m / z):[M + ]calcd.for C 38 H 32 N 10 O2S,693.25;found,693.26.
[0199] Synthesis Example 5
[0200] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0201]
[0202] , the preparation steps are as follows:
[0203] (1) Under nitrogen protection, 4-isoquinolineboronic acid (3.5 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (3.5 mmol), and Pd(PPh3)4 (0.3 mmol) were added to a reaction vessel, and the temperature was raised to 80°C and stirred for reaction for 24 hours. After the reaction, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 5 (yield 79%, 0.79 mmol).
[0204] The intermediate product 5 (0.79 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25°C for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.79 mmol) were dissolved in acetic acid, refluxed in an oil bath at 110°C for 12 hours, and then cooled and concentrated to obtain a residue, which was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 5 (yield 68%, 0.54 mmol, 319 mg), i.e., the dipyridophenazine compound of this synthetic example.
[0205] The characterization data of compound 5 are as follows:
[0206] 1 H NMR (500MHz, CDCl3): δ9.12(t,J=1.8Hz,2H),8.98(dd,J=4.3,2.0Hz,2H),8.83(dd,J=8.6,2.0Hz,2H),8.52(d,J=1.6Hz,2H),8.48–8.4 3(m,2H),7.95(dt,J=8.5,1.7Hz,2H),7.66(dd,J=8.5,4.1Hz,2H),7.57(ddd,J=8.3,7.1,1.3Hz,2H),7.51(ddd,J=8.6,7.0,1.5Hz,2H).
[0207] 13 C NMR (125MHz, CDCl3): δ154.76,151.30,150.82,150.12,146.75,146.31,141.76,134. 80,133.08,131.32,129.04,127.81,127.10,126.98,125.69,124.92,124.11,123.57.
[0208] FDMS(m / z):[M +]calcd.for C 36 H 18 N8S,595.14;found,595.15.
[0209] Synthesis Example 6
[0210] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0211] , the preparation steps are as follows:
[0212] (1) Under nitrogen protection, 2,6-bis(methoxycarbonyl)pyridine-4-boronic acid pinacol ester (3.5 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (2.8 mmol), and Pd(PPh3)4 (0.2 mmol) were added to a reaction vessel, and the temperature was raised to 80°C and stirred for reaction for 12 hours. After the reaction was completed, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 6 (yield 75%, 0.75 mmol).
[0213] (2) The intermediate product 6 (0.75 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25° C. for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.75 mmol) were dissolved in acetic acid, refluxed in an oil bath at 90° C. for 8 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 6 (yield 68%, 0.51 mmol, 370 mg), i.e., the dipyridophenazine compound of this synthetic example.
[0214] The characterization data of compound 6 are as follows:
[0215] 1 H NMR (500MHz, CDCl3): δ9.39 (s, 4H), 8.98 (dd, J = 4.3, 2.0 Hz, 2H), 8.83 (dd, J = 8.6, 2.0 Hz, 2H), 7.66 (dd, J = 8.5, 4.1 Hz, 2H), 3.93 (s, 12H).
[0216] 13C NMR (125MHz, CDCl3): δ165.72,159.68,151.30,147.41,147.18,146.75,141.75,138.97,134.80,126.55,124.92,123.57,122.71,52.87.
[0217] FDMS(m / z):[M + ]calcd.for C 36 H 22 N8O8S,727.13; found,727.14.
[0218] Synthesis Example 7
[0219] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0220] , the preparation steps are as follows:
[0221] (1) Under nitrogen protection, quinoline-4-boronic acid pinacol ester (3.0 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (3.0 mmol), and Pd(PPh3)4 (0.3 mmol) were added to a reaction vessel, and the temperature was raised to 90°C and stirred for reaction for 24 hours. After the reaction was completed, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 7 (yield 68%, 0.68 mmol).
[0222] (2) The intermediate product 7 (0.68 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25° C. for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.68 mmol) were dissolved in acetic acid, refluxed in an oil bath at 110° C. for 12 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 7 (yield 56%, 0.38 mmol, 226 mg), i.e., the dipyridophenazine compound of this synthetic example.
[0223] The characterization data of compound 7 are as follows:
[0224] 1H NMR (500MHz, CDCl3): δ8.98 (dd, J=4.3, 2.0Hz, 2H), 8.83 (dd, J=8.6, 2.0Hz, 2H), 8.38(d,J=4.6Hz,2H),8.35–8.28(m,2H),7.98–7.91(m,2H),7.71–7.63(m,8H).
[0225] 13 C NMR (125MHz, CDCl3): δ156.04,151.30,150.26,146.75,146.35,145.77,141.76,1 38.15,134.80,129.42,129.19,129.10,126.14,126.02,124.92,124.75,123.57.
[0226] FDMS(m / z):[M + ]calcd.for C 36 H 18 N8S,595.14;found,595.14.
[0227] Synthesis Example 8
[0228] This synthesis example provides a dipyridophenazine compound, the structural formula of which is The synthetic route is
[0229]
[0230] , the preparation steps are as follows:
[0231] (1) Under nitrogen protection, 7-azaindole-4-boric acid ester (3.5 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (2.5 mmol), and Pd(PPh3)4 (0.2 mmol) were added to a reaction vessel, and the temperature was raised to 80°C and stirred for reaction for 14 hours. After the reaction, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate 8 (yield 45%, 0.45 mmol).
[0232] (2) The intermediate product 8 (0.45 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25° C. for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.45 mmol) were dissolved in acetic acid, refluxed in an oil bath at 110° C. for 12 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product 8 (yield 68%, 0.31 mmol, 179 mg), i.e., the dipyridophenazine compound of this synthetic example.
[0233] The characterization data of compound 8 are as follows:
[0234] 1 H NMR (500MHz, CDCl3): δ9.75 (d, J=6.3Hz, 2H), 8.98 (dd, J=4.3, 2.0Hz, 2H), 8.83 (dd, J=8.6, 2.0Hz, 2H), 8.58 (d, J= 4.4Hz, 2H), 7.73 (d, J = 4.2Hz, 2H), 7.66 (dd, J = 8.5, 4.1Hz, 2H), 7.43 (dd, J = 6.4, 5.1Hz, 2H), 7.34 (d, J = 5.1Hz, 2H).
[0235] 13 C NMR (125MHz, CDCl3): δ155.96,151.30,147.87,146.75,145.22,144.07,141.76,1 34.80,132.57,124.92,124.59,123.57,122.45,118.37,116.27,116.26,104.71.
[0236] FDMS(m / z):[M + ]calcd.for C 32 H 16 N 10 S,573.14;found,573.15.
[0237] Synthesis Example 9
[0238] Synthesis Example 9 provides a dipyridophenazine compound having the structural formula The synthetic route is
[0239]
[0240] , the preparation steps are as follows:
[0241] Under nitrogen protection, pyridine-3-boric acid (3.5 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (2.5 mmol), and Pd(PPh3)4 (0.2 mmol) were added to a reaction vessel, the temperature was raised to 80°C and stirred for reaction for 24 hours. After the reaction, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate I (yield 49%, 0.49 mmol).
[0242] The intermediate I (0.49 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25°C for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.49 mmol) were dissolved in acetic acid, refluxed in an oil bath at 110°C for 12 hours, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product, compound 9, which is the dipyridophenazine compound prepared in this synthesis example (yield 72%, 0.31 mmol, 174 mg).
[0243] The characterization data of compound 9 are as follows:
[0244] 1 H NMR(500MHz,Chloroform-d)δ8.98(dd,J=4.3,2.0Hz,2H),8.83(dd,J=8.6,2.0Hz,2H),8.79–8.74(m,2H),8.6 5(dt,J=4.8,1.6Hz,2H), 7.79(dt,J=7.7,1.9Hz,2H), 7.66(dd,J=8.5,4.1Hz,2H), 7.46(dd,J=7.8,4.8Hz,2H).
[0245] 13 C NMR (125MHz, CDCl3): δ156.59,152.67,151.30,148.32,147.21,146.75,141.75,138.87,134.80,132.04,124.92,123.75,123.59,123.57.
[0246] FDMS(m / z):[M + ]calcd.for C 28 H 14N8S,495.11;found,495.12.
[0247] Synthesis Example 10
[0248] Synthesis Example 10 provides a dipyridophenazine compound having the structural formula The synthetic route is
[0249] , the preparation steps are as follows:
[0250] (1) Under nitrogen protection, 4-pyridineboronic acid pinacol ester (3.5 mmol), 4,7-dibromo-5,6-dinitrobenzothiadiazole (1.0 mmol), K2CO3 (2.5 mmol), and Pd(PPh3)4 (0.2 mmol) were added to a reaction vessel, and the temperature was raised to 80°C and stirred for reaction for 24 hours. After the reaction was completed, the mixture was cooled and diluted with water, extracted with EA, and purified to obtain intermediate II (yield 49%, 0.49 mmol).
[0251] (2) The intermediate product II (0.49 mmol) obtained in the previous step was added to a mixed solvent of DCM, methanol and water in a volume ratio of 1:1:1, and then ammonium chloride (20 mmol) and zinc powder (80 mmol) were added. The mixture was reacted at 25°C for 3 h, filtered, and the filter cake was washed with DCM. The filtrate was concentrated in vacuo to obtain a crude product. The crude product and 1,10-phenanthroline-5,6-dione (0.49 mmol) were dissolved in acetic acid, refluxed in an oil bath at 110°C for 12 h, and then cooled and concentrated to obtain a residue. The residue was purified by column chromatography using DCM / MeOH as an eluent to obtain the final product, compound 10, i.e., the dipyridophenazine compound of this synthetic example (yield 72%, 0.31 mmol, 174 mg).
[0252] The characterization data of compound 10 are as follows:
[0253] 1 H NMR (500MHz, Chloroform-d) δ8.98 (dd, J = 4.3, 2.0 Hz, 2H), 8.83 (dd, J = 8.6, 2.0 Hz, 2H), 8.70–8.63 (m, 4H), 7.66 (dd, J = 8.5, 4.1 Hz, 2H), 7.54–7.46 (m, 4H).
[0254] 13C NMR (125MHz, CDCl3): δ159.06,151.30,149.78,147.13,146.75,141.75,138.99,134.80,124.92,123.87,123.58,123.57.
[0255] FDMS(m / z):[M + ]calcd.for C 28 H 14 N8S,495.11;found,495.10.
[0256] Comparative Synthesis Example 1
[0257] Comparative Synthesis Example 1 provides a dipyridophenazine compound having the structural formula The synthetic route is The preparation steps are as follows:
[0258] 4,7-bis(5-(2-ethylhexyl)thiophen-2-yl)benzo[c][1,2,5]thiadiazole-5,6-diamine (1mmol) and 1,10-phenanthroline-5,6-dione (1mmol) were reacted in glacial acetic acid (100mL) under nitrogen protection at 120°C for 48h. After cooling to room temperature, the mixture was poured into methanol, and the crude product was purified by silica gel column chromatography using DCM / MeOH as eluent to obtain the product, which was the dipyridophenazine compound of Synthesis Comparative Example 1, recorded as D1 (yield 45%, 0.45mmol, 327mg).
[0259] The characterization data of the dipyridophenazine compound of Synthesis Comparative Example 1 are as follows:
[0260] 1 H NMR (500MHz, CDCl3) δ9.05 (t, J = 5.4Hz, 4H), 8.41 (s, 2H), 7.40 (s, 2H), 6.57 (s, 2H), 2.67 (s, 4H), 1.58–1.18 (m, 18H), 1.05–0.88 (m, 12H).
[0261] 13 C NMR (125MHz, CDCl3) δ152.1,150.5,150.2,148.8,140.7,135.2,134.1,133.8,13 3.2,127.4,125.3,123.6,119.6,41.4,33.6,32.7,29.1,25.6,23.0,14.3,11.0.
[0262] FDMS(m / z):[M +]calcd.for C 42 H 45 N6S3,729.28; found,729.28.
[0263] 2. Device Examples
[0264] Device Example 1
[0265] This device embodiment provides a perovskite solar cell, and the preparation steps are as follows:
[0266] (1) The ITO conductive glass was ultrasonically cleaned with deionized water, acetone and isopropanol for 15 minutes respectively, and finally dried in a drying oven at 75°C. The dried ITO conductive glass was treated in a UV ozone machine for 5 minutes to remove organic impurities on its surface and optimize its surface wettability.
[0267] (2) Nickel oxide nanoparticles were dispersed in deionized water to a concentration of 10 mg / mL. The solution containing the nickel oxide nanoparticles was then spin-coated on an ITO conductive glass at a speed of 2000 rpm for 30 seconds, and then annealed at 120° C. for 10 minutes to form a first hole transport sublayer with a thickness of 20 nm.
[0268] (2) Dissolve 1 mg of Me-4PACz in 1 mL of isopropyl alcohol (IPA) and stir at room temperature until completely dissolved to obtain a Me-4PACz solution. Then, spin coat the Me-4PACz solution on the first hole transport sublayer at a speed of 4000 rpm for 30 s. After the spin coating, anneal at 100°C for 10 min to obtain a second hole transport sublayer with a thickness of 10 nm.
[0269] (3) Dissolve 722.08 mg of lead iodide and 238.50 mg of iodomethylamine solid in 1 mL of N,N-dimethylformamide (DMF), and stir at room temperature until completely dissolved to obtain a perovskite precursor solution. In a nitrogen glove box, take 30 μL of the perovskite precursor solution and drop it onto the ITO conductive glass with a hole transport layer formed thereon. First, spin coat it at 1000 rpm for 10 seconds, then spin coat it at 5000 rpm for 30 seconds. When the spin coating lasts for 25 seconds, quickly drop 125 μL of chlorobenzene, then place the ITO conductive glass on a hot plate, and heat and anneal it at 100°C for 40 minutes to form a perovskite layer with a thickness of 300 nm.
[0270] (4) Take 10 mg of compound 1 prepared in Synthesis Example 1 (structural formula: ) was dissolved in 1 mL of 1,2-dichlorobenzene (DCB) and stirred at room temperature to obtain a uniform DCB mixed solution. 75 μL of the DCB mixed solution was dropped on the ITO conductive glass with a perovskite layer, and spin-coated at 3000 rpm for 30 seconds to form an electron transport layer with a thickness of 20 nm.
[0271] (5) Subsequently, an ethanol solution of BCP (0.5 mg / mL) was spin-coated on the electron transport layer to obtain a hole blocking layer with a thickness of 8 nm.
[0272] (6) Transfer the ITO conductive glass formed with the hole blocking layer, electron transport layer, perovskite layer, and hole transport layer to the vacuum coating instrument and wait until the vacuum degree is drawn to 3*10 -4 Pa, a silver electrode is evaporated to form a silver electrode with a thickness of 100 nm, thereby obtaining the perovskite solar cell of the device embodiment.
[0273] Device Example 2
[0274] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 2 prepared in synthesis embodiment 2, and the structural formula is The concentration of the mixed solution prepared with DCB is 10 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0275] Device Example 3
[0276] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 3 prepared in synthesis embodiment 3, and the structural formula is: The concentration of the mixed solution prepared with DCB is 10 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0277] Device Example 4
[0278] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 4 prepared in synthesis embodiment 4, and the structural formula is: The concentration of the mixed solution prepared with DCB is 20 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0279] Device Example 5
[0280] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 5 prepared in synthesis embodiment 5, and the structural formula is: The concentration of the mixed solution prepared with DCB is 5 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0281] Device Example 6
[0282] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 6 prepared in synthesis embodiment 6, and the structural formula is: The concentration of the mixed solution prepared with DCB is 20 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0283] Device Example 7
[0284] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 7 prepared in synthesis embodiment 7, and the structural formula is: The concentration of the mixed solution prepared with DCB is 5 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0285] Device Example 8
[0286] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 8 prepared in synthesis embodiment 8, and the structural formula is: The concentration of the mixed solution prepared with DCB is 10 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0287] Device Example 9
[0288] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 9 prepared in synthesis embodiment 9, and the structural formula is: The concentration of the mixed solution prepared with DCB is 3 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0289] Device Example 10
[0290] This device embodiment provides a perovskite solar cell, and the preparation steps are similar to those of device embodiment 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is compound 10 prepared in synthesis embodiment 10, and the structural formula is: The concentration of the mixed solution prepared with DCB is 3 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0291] Device Comparison Example 1
[0292] Device Comparative Example 1 provides a perovskite solar cell, and the preparation steps are similar to those of Device Example 1, except that the material used for the electron transport layer is different. In this device embodiment, the material used for the electron transport layer is the compound D1 prepared in Synthesis Comparative Example 1, and the structural formula is: The concentration of the mixed solution prepared with DCB is 20 mg / mL. The other steps are the same as those in device embodiment 1 and will not be described in detail.
[0293] The performance tests were performed on the device embodiments 1 to 10 and the device comparative example 1, and the experimental data shown in the following Table 1 were obtained.
[0294] Table 1 Performance test of device embodiments 1 to 10 and device comparative example 1
[0295]
[0296] It can be seen from the data in Table 1 that the modified dipyridophenazine compounds all have excellent device performance, and the optoelectronic performance of the device embodiments can be further improved by optimizing the substituents.
[0297] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0298] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several modifications and improvements can be made, which all belong to the scope of protection of the present application. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the scope of protection of the claims attached to the present application. Therefore, the scope of protection of the patent of this application shall be based on the contents of the attached claims, and the description and drawings can be used to explain the contents of the claims.
Claims
1. A dipyridophenazine compound, characterized in that: It has the following general structural formula: Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
2. The dipyridophenazine compound according to claim 1, characterized in that: Each L is independently substituted or unsubstituted C5 to C 10 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C5~C 10 A nitrogen-containing heteroaryl group; Optionally, each L is independently one of a substituted or unsubstituted pyridyl, pyrazolyl, pyrrolyl, pyrazolopyridyl, pyrrolopyridyl, quinolyl and isoquinolyl.
3. The dipyridophenazine compound according to claim 2, characterized in that: The bipyridophenazine compound has the following general structural formula: In the formula, R represents the substituent, and m is an integer of 0-4.
4. The dipyridophenazine compound according to any one of claims 1 to 3, characterized in that: Each of the substituents is independently selected from one of halogen, amide, ester, carboxyl and carbonyl; Optionally, each of the substituents is independently selected from one of halogen, C1-C6 amide and C1-C6 ester.
5. The dipyridophenazine compound according to claim 4, characterized in that: Selected from one or more of the following structural formulas:
6. A method for preparing a dipyridophenazine compound, characterized in that: The steps include: Reacting compound c with 1,10-phenanthroline-5,6-dione to generate a dipyridophenazine compound; Wherein, the structural formula of the compound c is The structural formula of the dipyridophenazine compound is In the formula, each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group, when substituted, is selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
7. The preparation method according to claim 6, characterized in that: The compound C is prepared by the following steps: allowing compound a to react with 4,7-dibromo-5,6-dinitrobenzothiadiazole to generate compound b; Reducing the nitro group in the compound b to generate the compound c; Wherein, the structural formula of the compound a is Or L—B(OH)2, the structural formula of compound b is 8. Use of the dipyridophenazine compound according to any one of claims 1 to 5 or the dipyridophenazine compound prepared by the preparation method according to any one of claims 6 to 7 in the preparation of semiconductor devices.
9. A photoelectric device, characterized in that: The invention comprises a first electrode, a second electrode and a functional layer arranged between the first electrode and the second electrode, wherein the material of the functional layer comprises a dipyridophenazine compound, and the dipyridophenazine compound has the following general structural formula: Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group is substituted with a substituent selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
10. The optoelectronic device according to claim 9, characterized in that: The functional layer includes an electron transport layer, and the photoelectric device further includes a photoelectric conversion layer and a hole transport layer disposed between the first electrode and the second electrode, wherein the photoelectric conversion layer is disposed between the electron transport layer and the hole transport layer.
11. A method for preparing a photoelectric device, characterized in that: The steps include: Forming a first electrode, a second electrode and a functional layer in a stacked arrangement, wherein the functional layer is stacked between the first electrode and the second electrode, to prepare a photoelectric device; Wherein, the material of the functional layer includes a dipyridophenazine compound, and the dipyridophenazine compound has the following general structural formula: Each L is independently substituted or unsubstituted C4 to C 20 A nitrogen-containing heterocyclic group, or a substituted or unsubstituted C4~C 20 The nitrogen-containing heteroaryl group is substituted with a substituent selected from nitro, halogen, amide, cyano, carboxyl, carbonyl, ester, C1-C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 10 Cycloalkyl, C3~C 10 Heterocycloalkyl, C5~C 10 Aryl, C5~C 10 Heteroaryl, -C n OR1 and -C n SR1; wherein each R1 is independently selected from hydrogen, C1 to C 10 Alkyl, C1~C 10 Heteroalkyl, C3~C 20 Cycloalkyl, C3~C 10 Heterocycloalkyl and C4~C 10 One of the cycloalkylalkyl groups; n represents an integer between 0 and 10.
12. The method for preparing a photoelectric device according to claim 11, characterized in that: The functional layer is prepared by a solution method, and a functional material is dissolved in a solvent to make the concentration of the functional material be 1 mg / mL to 20 mg / mL, wherein the functional material includes the dipyridophenazine compound; Optionally, the functional layer comprises an electron transport layer.
